Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-6
|
pubmed:dateCreated |
1990-3-30
|
pubmed:abstractText |
The biological activities of tamoxifen derivatives that contain various side chain alterations were studied using a T47D breast cancer cell growth assay in vitro. We studied the activity of various analogs to determine the important aspects of side chain composition and aryl ring positioning on antiestrogenic activity. Previous studies utilizing a rat pituitary cell prolactin synthesis assay have shown that substitution of the aminoethoxy side chain for an allyl side chain resulted in agonist activity, whereas the addition of a glyceryl side chain produced antiestrogenic activity. In the present study utilizing T47D cells, compounds with alkyl or allyl substitutions were partial agonists, as were compounds with bulky para-substituted benzyl group constituents. A tamoxifen derivative with a side chain containing an ethyl ester was antiestrogenic (IC50 = 2 x 10(-6) M) and effectively inhibited estradiol (10(-10) M) stimulation of growth. However, a compound with a short similar methyl ester-containing side chain did not possess any activity. Compounds with carbinol-containing side chains were antiestrogenic (IC50 = 2.8-3.5 x 10(-7) M). All of the compounds displaying antiestrogenic activity could be "rescued" by incubation with estradiol (10(-8) M) and therefore were not nonspecifically toxic to the cells. These results support the hypothesis that the presence of a lone pair of electrons within the side chain region of tamoxifen may be required for antiestrogenic activity. Also, nonplanar placement of the aryl ring of the triphenylethylene-type of compound is critical for potency.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0022-4731
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
34
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
407-11
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:2626034-Breast Neoplasms,
pubmed-meshheading:2626034-Cell Division,
pubmed-meshheading:2626034-Cell Line,
pubmed-meshheading:2626034-Drug Screening Assays, Antitumor,
pubmed-meshheading:2626034-Female,
pubmed-meshheading:2626034-Humans,
pubmed-meshheading:2626034-Structure-Activity Relationship,
pubmed-meshheading:2626034-Tamoxifen,
pubmed-meshheading:2626034-Tumor Cells, Cultured
|
pubmed:year |
1989
|
pubmed:articleTitle |
Structural components necessary for the antiestrogenic activity of tamoxifen.
|
pubmed:affiliation |
Department of Human Oncology, University of Wisconsin Clinical Cancer Center, Madison 53792.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|